CB-618
CB-618 is a β-lactamase inhibitor. CB-618 reversibly covalently inhibits Ambler class A, C, and some class D serine β-lactamases. CB-618 has weak antibacterial activity as a single agent, but it significantly enhances the antibacterial activity of Meropenem (HY-13678) against enzyme-producing Enterobacteriaceae. CB-618 can be used in research on drug-resistant bacteria.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1463520-70-8
- 分子式: C8H10N4O6S
- 分子量:290.25
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Beta-lactamase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
化学情報
-
CAS 番号 1463520-70-8
-
分子量 290.25
-
分子式 C8H10N4O6S
-
SMILES
O=S(ON1[C@]2([H])CC[C@@H](C3=NN=CO3)[N@@](C2)C1=O)(O)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
純度とドキュメンテーション
参考文献
[1]. Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors in the clinic. Infectious disease clinics of North America. 2016 Jun;30(2):441. [Content Brief]
[2]. Griffith DC, et al. Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrobial Agents and Chemotherapy. 2019 Jan;63(1):10-128. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)